MX2012011881A - Metodos para tratar trastornos metabolicos de glucosa. - Google Patents
Metodos para tratar trastornos metabolicos de glucosa.Info
- Publication number
- MX2012011881A MX2012011881A MX2012011881A MX2012011881A MX2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- metabolic disorders
- glucose metabolic
- treating glucose
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
En un aspecto, la invención se refiere a métodos para tratar una enfermedad o condición asociada con metabolismo anormal de glucosa. En otro aspecto, la invención se refiere a un método para reducir incidencia o progresión de diabetes mellitus dependiente de insulina. Los métodos incluyen administrar oralmente a un mamífero en necesidad de ello una cantidad efectiva de una composición, la cual incluye un material que se presenta naturalmente derivado de cascarán de huevo, membrana de cascarón de huevo, o una combinación de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32330310P | 2010-04-12 | 2010-04-12 | |
| PCT/US2011/032103 WO2011130261A1 (en) | 2010-04-12 | 2011-04-12 | Methods for treating glucose metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012011881A true MX2012011881A (es) | 2013-04-19 |
Family
ID=44798988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012011881A MX2012011881A (es) | 2010-04-12 | 2011-04-12 | Metodos para tratar trastornos metabolicos de glucosa. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8679551B2 (es) |
| EP (2) | EP2557920B1 (es) |
| CN (2) | CN105250335B (es) |
| AU (1) | AU2011240764B2 (es) |
| CA (1) | CA2796336C (es) |
| CY (2) | CY1116808T1 (es) |
| ES (2) | ES2528413T3 (es) |
| MX (1) | MX2012011881A (es) |
| NZ (1) | NZ602949A (es) |
| PL (2) | PL2842563T3 (es) |
| PT (2) | PT2557920E (es) |
| RS (2) | RS55025B1 (es) |
| WO (1) | WO2011130261A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2440390B1 (es) * | 2012-07-25 | 2014-11-13 | Bioibérica, S.A. | Composiciones para el tratamiento del sobrepeso y de la obesidad |
| JP5998350B2 (ja) * | 2013-03-27 | 2016-09-28 | 国立大学法人 東京大学 | 卵殻膜成分を含む肝保護剤ならびにそれを用いた医薬組成物、食品添加物および食品 |
| JP2014231487A (ja) * | 2013-05-28 | 2014-12-11 | 国立大学法人 東京大学 | 卵殻膜成分を含むサーチュイン遺伝子活性化剤ならびにそれを用いた組成物 |
| US20140363519A1 (en) * | 2013-06-11 | 2014-12-11 | The University Of Tokyo | Activator of gene expression of molecular chaperone gene comprising eggshell membrane component and composition thereof |
| EP3643320A1 (en) * | 2013-07-08 | 2020-04-29 | International Dehydrated Foods, Inc. | Compositions prepared from poultry and methods of their use |
| US11478504B2 (en) | 2013-07-08 | 2022-10-25 | International Dehydrated Foods, Inc. | Compositions and methods for preventing/treating metabolic syndrome |
| JP6056064B2 (ja) * | 2013-11-29 | 2017-01-11 | 国立大学法人 東京大学 | 卵殻膜成分を含むインスリン抵抗性改善剤ならびにそれを用いた組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5652221A (en) * | 1994-11-07 | 1997-07-29 | The University Of Virginia Patent Foundation | Method of treating defective glucose metabolism using synthetic insulin substances |
| GB0213612D0 (en) * | 2002-06-13 | 2002-07-24 | Novartis Nutrition Ag | Organic compounds |
| DE20213669U1 (de) * | 2002-09-02 | 2004-02-12 | Ewald Speth Antriebstechnik Gmbh | Direkt angetriebene Antriebsachse mit einer an axial festgelegtes Sonnenritzel aufweisenden Getriebestufe |
| US20080063677A1 (en) * | 2004-03-10 | 2008-03-13 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
| KR100662903B1 (ko) * | 2004-12-14 | 2007-01-02 | 건국대학교 산학협력단 | 글루코사민 하이드로클로라이드를 함유하는 당뇨 질환치료용 의약 조성물 |
| CA2556343A1 (en) * | 2005-09-01 | 2007-03-01 | Purepharm Inc. | Synthetic nutritional formulations |
| CN102325535A (zh) * | 2009-02-23 | 2012-01-18 | 帝斯曼知识产权资产管理有限公司 | 用于炎性病症的cajanus提取物和葡糖胺 |
-
2011
- 2011-04-12 EP EP11769433.1A patent/EP2557920B1/en active Active
- 2011-04-12 EP EP14182072.0A patent/EP2842563B1/en active Active
- 2011-04-12 US US13/640,607 patent/US8679551B2/en active Active
- 2011-04-12 WO PCT/US2011/032103 patent/WO2011130261A1/en active Application Filing
- 2011-04-12 AU AU2011240764A patent/AU2011240764B2/en active Active
- 2011-04-12 PT PT117694331T patent/PT2557920E/pt unknown
- 2011-04-12 RS RS20160484A patent/RS55025B1/sr unknown
- 2011-04-12 CN CN201510567716.4A patent/CN105250335B/zh active Active
- 2011-04-12 RS RS20150051A patent/RS53826B1/en unknown
- 2011-04-12 PT PT141820720T patent/PT2842563T/pt unknown
- 2011-04-12 NZ NZ602949A patent/NZ602949A/en unknown
- 2011-04-12 PL PL14182072.0T patent/PL2842563T3/pl unknown
- 2011-04-12 MX MX2012011881A patent/MX2012011881A/es unknown
- 2011-04-12 PL PL11769433T patent/PL2557920T3/pl unknown
- 2011-04-12 CN CN201180029018.9A patent/CN103002736B/zh active Active
- 2011-04-12 CA CA2796336A patent/CA2796336C/en active Active
- 2011-04-12 ES ES11769433.1T patent/ES2528413T3/es active Active
- 2011-04-12 ES ES14182072.0T patent/ES2579340T3/es active Active
-
2014
- 2014-03-13 US US14/209,214 patent/US8927032B2/en active Active
-
2015
- 2015-01-19 CY CY20151100052T patent/CY1116808T1/el unknown
-
2016
- 2016-06-30 CY CY20161100599T patent/CY1117799T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011240764B2 (en) | 2014-07-10 |
| AU2011240764A1 (en) | 2012-11-08 |
| EP2842563B1 (en) | 2016-05-25 |
| EP2557920B1 (en) | 2014-11-12 |
| WO2011130261A1 (en) | 2011-10-20 |
| CA2796336C (en) | 2018-06-05 |
| US20130089619A1 (en) | 2013-04-11 |
| PL2557920T3 (pl) | 2015-04-30 |
| ES2528413T3 (es) | 2015-02-10 |
| RS55025B1 (sr) | 2016-11-30 |
| US8927032B2 (en) | 2015-01-06 |
| RS53826B1 (en) | 2015-06-30 |
| CN105250335A (zh) | 2016-01-20 |
| EP2557920A4 (en) | 2013-10-23 |
| PT2557920E (pt) | 2015-02-05 |
| US8679551B2 (en) | 2014-03-25 |
| CN103002736B (zh) | 2015-11-25 |
| PL2842563T3 (pl) | 2016-12-30 |
| PT2842563T (pt) | 2016-07-14 |
| CN103002736A (zh) | 2013-03-27 |
| EP2557920A1 (en) | 2013-02-20 |
| US20140193516A1 (en) | 2014-07-10 |
| CN105250335B (zh) | 2019-10-29 |
| CY1116808T1 (el) | 2017-03-15 |
| ES2579340T3 (es) | 2016-08-10 |
| NZ602949A (en) | 2014-11-28 |
| CA2796336A1 (en) | 2011-10-20 |
| EP2842563A1 (en) | 2015-03-04 |
| CY1117799T1 (el) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012011881A (es) | Metodos para tratar trastornos metabolicos de glucosa. | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| AU2018253580A1 (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| PH12016501607A1 (en) | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | |
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
| MX344925B (es) | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. | |
| WO2013158928A3 (en) | Chemosensory receptor ligand-based therapies | |
| WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
| EP2506717A4 (en) | METHOD OF USING DOPAMINE RECAPTURE INHIBITORS AND THEIR ANALOGUES TO TREAT DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES ASSOCIATED DISEASE CONDITIONS | |
| WO2013055834A3 (en) | Er stress relievers in beta cell protection | |
| EP2560660A4 (en) | THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS | |
| GB201101459D0 (en) | Novel compounds and thier effects on fedding behaviour | |
| AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
| WO2013186240A3 (en) | Exendin-4 peptide analogues | |
| WO2012097213A3 (en) | Methods for diagnosing and treating eye-length related disorders | |
| GB201317446D0 (en) | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow | |
| MX2013013307A (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| WO2013041519A9 (en) | Ror gamma modulators | |
| AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
| WO2014036528A3 (en) | Agents useful for treating obesity, diabetes and related disorders | |
| MX2011012666A (es) | Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares. | |
| EP2646032A4 (en) | THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND TYPE 2 DIABETES, ADIPOSITAS OR PREDICTES | |
| WO2011063161A3 (en) | Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr) | |
| WO2010106542A3 (en) | USE OF NKp46 FOR PREVENTING DIABETES |